The impact of new cancer drugs in real practice oncology: A monoinstitutional experience

Immunopharmacology and Immunotoxicology

Volumn 34, Issue 4, 2012, Pages 702-705

  Jirillo, Antonio ^a   Imbevaro, Silvia ^a   Mazurek, Magdalena ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Analysis; Appropriateness; Cancer chemotherapy; Drug target; Economic cost; Real practice oncology

Indexed keywords

BEVACIZUMAB; CETUXIMAB; ERLOTINIB; FULVESTRANT; PANITUMUMAB; PEMETREXED; SORAFENIB; SUNITINIB;

AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CLINICAL PRACTICE; COLON CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; RECTUM CANCER; TREATMENT REFUSAL; TREATMENT WITHDRAWAL;

ANTINEOPLASTIC AGENTS; COSTS AND COST ANALYSIS; FEMALE; HUMANS; ITALY; MALE; NEOPLASMS; REGISTRIES; WITHHOLDING TREATMENT;

EID: 84863807776     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923973.2011.648268     Document Type: Article

References (9)

1. Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N.J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I.F., Fojo, T., Siderov, J., Williamson, S., Camporesi, S., McVie, J.G., Purushotham, A.D., Naredi, P., Eggermont, A., Brennan, M.F., Steinberg, M.L., De Ridder, M., McCloskey, S.A., Verellen, D., Roberts, T., Storme, G., Hicks, R.J., Ell, P.J., Hirsch, B.R., Carbone, D.P., Schulman, K.A., Catchpole, P., Taylor, D., Geissler, J., Brinker, N.G., Meltzer, D., Kerr, D., Aapro, M. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12, 933-980.
2. Thomas, J.S., Bruce, E.H. Bending the cost curve in cancer care. N Engl J Med 2011, 364, 2060-2065.
3. Stark, C.J. The economic burden of cancer in Europe. EJHP Practice. 2006, 12, 53-56.
4. Mack, J.W., Weeks, J.C., Wright, A.A., Block, S.D., Prigerson, H.G. End-of-life discussions, goal attainment, and distress at the end of life: Predictors and outcomes of receipt of care consistent with preferences. J Clin Oncol 2010, 28, 1203-1208.
5. Zhang, B., Wright, A.A., Huskamp, H.A., Nilsson, M.E., Maciejewski, M.L., Earle, C.C., Block, S.D., Maciejewski, P.K., Prigerson, H.G. Health care costs in the last week of life: Associations with end-of-life conversations. Arch Intern Med 2009, 169, 480-488.
6. Earle, C.C., Landrum, M.B., Souza, J.M., Neville, B.A., Weeks, J.C., Ayanian, J.Z. Aggressiveness of cancer care near the end of life: Is it a quality-of-care issue? J Clin Oncol 2008, 26, 3860-3866.
7. Temel, J.S., Greer, J.A., Muzikansky, A., Gallagher, E.R., Admane, S., Jackson, V.A., Dahlin, C.M., Blinderman, C.D., Jacobsen, J., Pirl, W.F., Billings, J.A., Lynch, T.J. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010, 363, 733-742.
8. Trojniak, M.P., Palozzo, A.C., Mazurek, M., Jirillo, A. Sorafenib in hepatocellular carcinoma- A post marketing evaluation. Immunopharmacol Immunotoxicol 2011. Oct 8. [Epub ahead of print]
9. Jirillo, A., Boscaro, M., Pasetto, L.M., Monfardini, S. Chemotherapy at the end of life: An open question. Tumori 2005, 91, 104-105.